Giripladib

DB15426InvestigationalSmall molecule

Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).

Mechanism: Pharmacologically active on Cytosolic phospholipase A2
Curator reviewed
Formula / weight: C₄₁H₃₆ClF₃N₂O₄S · 745.25 g/mol (avg)
Code names: PLA-695

Resolves to

Compound

UNII1W10Q5H7WDCAS865200-20-0ChEMBLCHEMBL2104969

Structure

InChIKeyNHHBNHIPCSPSHQ-UHFFFAOYSA-NSMILESOC(=O)C1=CC=C(CCCC2=C(CCNS(=O)(=O)CC3=C(C=CC=C3)C(F)(F)F)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C3=C2C=C(Cl)C=C3)C=C1

Targets

P47712PLA2G4A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Giripladib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account